Takeda Pharmaceutical Receives FDA Approval for Ready-to-Use Liquid Immunoglobulin Therapy
MT Newswires Live
Jun 30, 2025
Takeda Pharmaceutical (TAK) said Monday it received US Food and Drug Administration approval for Gammagard Liquid erc, a ready-to-use liquid immunoglobulin therapy for the treatment of primary immunodeficiency in patients aged two and older.
Takeda said US commercialization is expected in 2026, followed by a European Union launch by 2027, where the therapy is approved.
The company said it will discontinue manufacturing of its older freeze-dried formulation Gammagard s/d by the end of 2027 due to supply limitations.
Shares of Takeda were up past 1% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.